An interventional study of nomogram in Astigmatism, sponsored by Tianjin Eye Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Tianjin Eye Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Astigmatism with a site in China — 11 open to participants now, 13 under way, none of them phase 3. Astigmatism · China.
Among the 29 studies in Astigmatism with a site in China, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2025, is one of 16 with no phase, reaches primary completion later than 9 of the 12 other live ones, and was the 28th registered.
418 studies on the registry are indexed under Astigmatism; 51 are open to participants now.
Browse Astigmatism studies →11 of the 29 studies in Astigmatism with a site in China are open now. Recruiting first, the newest first:
Jin Yang · Sites in China
Jin Yang · Sites in China
Ages 18+
Eye & ENT Hospital of Fudan University · Sites in China
Ages 20–80
Jin Yang · Sites in China
Ages 18+
Tianjin Eye Hospital · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 55 across 326 interventional studies indexed under Astigmatism.
Median enrollment 100 across the 17 interventional studies, 492 across the 12 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 29 have an industry lead sponsor. The 10 most frequent:
Tianjin Eye Hospital is the lead sponsor of 53 studies on the registry; 18 are open to participants now.
Tianjin Eye Hospital has 5 studies filed under Astigmatism — fewer than ten, so there is no comparison to draw.
2 of the studies in Astigmatism with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07605221Tianjin Eye HospitalNomogram for Astigmatism Correction of KLEx | 2026-12-31 |
| NCT03299530Wenzhou Medical UniversityAccuracy of Corneal Astigmatism in Different Region Modes | 2027-06-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Astigmatism with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if nomogram could promote treatment outcomes in astigmatism correction. The main question it aims to answer is:
does the nomogram could promote treatment outcomes in astigmatism correction? If there is a comparison group: Researchers will compare non-nomogram adopted to see if the outcome acceptable.
Participants will ask to complete 3-month follow-up of manifest refraction and visual acuity test.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
astigmatism was corrected with nomogram adjustment
Procedure: nomogram
astigmatism was corrected without nomogram adjustment
nomogram was added to nomogram group
residual astigmstism
Time frame: 3 months
visual acuity
Time frame: 3 months
Plan to share: Undecided
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
Of 77 non-industry interventional studies with no phase under Astigmatism, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 22 months is above that.
Counting every sponsor, half of 183 studies reached it within 12 months; a quarter within 4 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tianjin Eye Hospital